Hongzhang Yang, Xinying Zeng, Jia Liu, Jingchao Li, Yun Li, Qinglin Zhang, Linlin Shu, Huanhuan Liu, Xueqi Wang, Yuanyuan Liang, Ji Hu, Lumei Huang, Zhide Guo, Xianzhong Zhang
BACKGROUND: Radiotheranostics differs from the vast majority of other cancer therapies in its capacity for simultaneous imaging and therapy, and it is becoming more widely implemented. A balance between diagnostic and treatment requirements is essential for achieving effective radiotheranostics. Herein, we propose a proof-of-concept strategy aiming to address the profound differences in the specific requirements of the diagnosis and treatment of radiotheranostics. RESULTS: To validate the concept, we designed an s-tetrazine (Tz) conjugated prostate-specific membrane antigen (PSMA) ligand (DOTA-PSMA-Tz) for 68 Ga or 177 Lu radiolabeling and tumor radiotheranostics, a trans-cyclooctene (TCO) modified Pd@Au nanoplates (Pd@Au-PEG-TCO) for signal amplification, respectively...
March 10, 2024: Journal of Nanobiotechnology